<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00269217</url>
  </required_header>
  <id_info>
    <org_study_id>0524B-022</org_study_id>
    <secondary_id>MK0524B-022</secondary_id>
    <secondary_id>2005_098</secondary_id>
    <nct_id>NCT00269217</nct_id>
  </id_info>
  <brief_title>Lipid Efficacy Study (0524B-022)(COMPLETED)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, &quot;Factorial&quot; Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Coadministered MK0524B Tablets in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This is a 12-week clinical trial in patients with primary hypercholesterolemia or mixed
      hyperlipidemia, studying the effects of coadministered MK0524B on lipids. There will be 6
      scheduled clinic visits, and 7 treatment arms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coadministered MK0524B will be more efficacious in reducing LDL-C concentrations compared to MK0524A.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coadministered MK0524B will have a greater effect on HDL-C, TG, LDL-C, LDL-C:HDL-C, non-HDL-C, Apo B, and Apo A-I than simvastatin.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coadministered MK0524B will have a greater effect on HDL-C, TG, LDL-C:HDL-C, non-HDL-C, Apo B, and Apo A-I than MK0524A.</measure>
  </secondary_outcome>
  <enrollment type="Actual">1400</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <condition>Mixed Hyperlipidemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>niacin (+) laropiprant (+) simvastatin</intervention_name>
    <description>Duration of Treatment 12 Weeks</description>
    <other_name>MK0524B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: niacin (+) laropiprant</intervention_name>
    <description>Duration of Treatment 12 Weeks</description>
    <other_name>MK0524A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: simvastatin</intervention_name>
    <description>Duration of Treatment 12 Weeks</description>
    <other_name>MK0733</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 to 85 years of age with primary hypercholesterolemia or mixed
             hyperlipidemia

          -  LDL-C between 130 and 190 mg/L (Category I) and 130 and 160 mg/L (Category II) and
             triglycerides &lt;/= 350 mg/dL.

        Exclusion Criteria:

          -  A condition which, in the opinion of the investigator, might pose a risk to the
             patient or interfere with participating in the study

          -  Patients with &lt;80% compliance

          -  Patients with certain medical conditions

          -  Patients taking certain concomitant medications and/or with unstable doses of
             medications

          -  Or those with a history of CHD/CHD equivalent or diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2005</study_first_submitted>
  <study_first_submitted_qc>December 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2005</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type V</mesh_term>
    <mesh_term>Lipidoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis Link</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

